StreetInsider.com News Articles

At ASCO and EHA 2026, New Data Reinforce the Pivotal Role of clonoSEQ® MRD Testing Across Hematology Clinical Practice and Research

Fri, 29 May 2026 07:30:00 -0400

Over 30 scientific presentations leverage clonoSEQ MRD testing to assess novel therapies and support MRD-guided patient care across blood cancers

SEATTLE, May 29, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced that its next-generation sequencing (NGS)-based clonoSEQ^® test for measurable residual disease (MRD) assessment will be included in 33 presentations, including one plenary session and 14 oral presentations, across the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29-June

At ASCO and EHA 2026, New Data Reinforce the Pivotal Role of clonoSEQ® MRD Testing Across Hematology Clinical Practice and Research

Fri, 29 May 2026 07:30:00 -0400

Over 30 scientific presentations leverage clonoSEQ MRD testing to assess novel therapies and support MRD-guided patient care across blood cancers

Adaptive Biotechnologies to Participate in Upcoming Investor Conferences

Thu, 21 May 2026 16:17:00 -0400

SEATTLE, May 21, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial-stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the following investor conferences.

Craig-Hallum 23rd Annual Institutional Investor Conference – Minneapolis, MN
Hosting 1x1 meetings on Thursday, May 28th
William Blair 46th Annual Growth Stock Conference – Chicago, IL
Presentation on Wednesday, June 3rd at 3:20 p.m. Central Time

Interested parties may access a live and archived webcast of the presentation from the William Blair Growth Stock Conference on the “Investors” section of

Adaptive Biotechnologies to Participate in Upcoming Investor Conferences

Thu, 21 May 2026 16:17:00 -0400

Craig-Hallum 23rd Annual Institutional Investor Conference – Minneapolis, MN
Hosting 1x1 meetings on Thursday, May 28th
William Blair 46th Annual Growth Stock Conference – Chicago, IL
Presentation on Wednesday, June 3rd at 3:20 p.m. Central Time

Interested parties may access a live and archived webcast of the presentation from the William Blair Growth Stock Conference on the “Investors” section of

Adaptive Biotechnologies to Participate in Upcoming Investor Conferences

Thu, 21 May 2026 16:17:00 -0400

Craig-Hallum 23rd Annual Institutional Investor Conference – Minneapolis, MN
Hosting 1x1 meetings on Thursday, May 28th
William Blair 46th Annual Growth Stock Conference – Chicago, IL
Presentation on Wednesday, June 3rd at 3:20 p.m. Central Time

Interested parties may access a live and archived webcast of the presentation from the William Blair Growth Stock Conference on the “Investors” section of

Adaptive Biotechnologies to Participate in Upcoming Investor Conferences

Thu, 21 May 2026 16:17:00 -0400

Craig-Hallum 23rd Annual Institutional Investor Conference – Minneapolis, MN
Hosting 1x1 meetings on Thursday, May 28th
William Blair 46th Annual Growth Stock Conference – Chicago, IL
Presentation on Wednesday, June 3rd at 3:20 p.m. Central Time

Interested parties may access a live and archived webcast of the presentation from the William Blair Growth Stock Conference on the “Investors” section of

Form 4 Adaptive Biotechnologies For: May 18 Filed by: PISKEL KYLE

Wed, 20 May 2026 19:14:00 -0400

si-local-file:///var/storage/secattach/20260520/26529914.html

Form 4 Adaptive Biotechnologies For: May 18 Filed by: PISKEL KYLE

Wed, 20 May 2026 19:14:00 -0400

si-local-file:///var/storage/secattach/20260520/26529914.html

Form 144 Adaptive Biotechnologies Filed by: PISKEL KYLE

Fri, 15 May 2026 20:04:00 -0400

si-local-file:///var/storage/secattach/20260515/26508404.html

Form 144 Adaptive Biotechnologies Filed by: PISKEL KYLE

Fri, 15 May 2026 20:04:00 -0400

si-local-file:///var/storage/secattach/20260515/26508404.html

Form SCHEDULE 13G/A Adaptive Biotechnologies Filed by: VIKING GLOBAL INVESTORS LP

Fri, 15 May 2026 17:51:00 -0400

si-local-file:///var/storage/secattach/20260515/26508110.html

Form SCHEDULE 13G/A Adaptive Biotechnologies Filed by: VIKING GLOBAL INVESTORS LP

Fri, 15 May 2026 17:51:00 -0400

si-local-file:///var/storage/secattach/20260515/26508110.html

Adeptus Biotechnologies Corp. (ADPT) PT Lowered to $18 at Morgan Stanley

Tue, 12 May 2026 08:34:42 -0400

Morgan Stanley analyst Kallum Titchmarsh lowered the price target on Adeptus Biotechnologies Corp. (NASDAQ: ADPT) to $18.00 (from $21.00) while maintaining a Equalweight rating.

Adaptive Biotechnologies Corp. (ADPT) PT Lowered to $19 at JPMorgan

Wed, 06 May 2026 09:11:38 -0400

JPMorgan analyst Sebastian Sandler lowered the price target on Adaptive Biotechnologies Corp. (NASDAQ: ADPT) to $19.00 (from $21.00) while maintaining a Overweight rating.

Adeptus Biotechnologies Corp. (ADPT) PT Raised to $21 at TD Cowen

Wed, 06 May 2026 08:17:27 -0400

TD Cowen analyst Dan Brennan raised the price target on Adeptus Biotechnologies Corp. (NASDAQ: ADPT) to $21.00 (from $19.00) while maintaining a Buy rating.

Form 10-Q Adaptive Biotechnologies For: Mar 31

Tue, 05 May 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260505/26435556.html

Form 10-Q Adaptive Biotechnologies For: Mar 31

Tue, 05 May 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260505/26435556.html

Form 8-K Adaptive Biotechnologies For: May 05

Tue, 05 May 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260505/26435036.html

Form 8-K Adaptive Biotechnologies For: May 05

Tue, 05 May 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260505/26435036.html

Adaptive Biotechnologies Reports First Quarter 2026 Financial Results

Tue, 05 May 2026 16:05:00 -0400

SEATTLE, May 05, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended March 31, 2026.

“We delivered strong first quarter results based on accelerating adoption of MRD across both clinical testing and drug development. Our performance reinforces our market leadership position and the differentiated value of our platform,” said Chad Robins, chief executive officer and co-founder of Adaptive Biotechnologies. “With disciplined execution and

Adaptive Biotechnologies Reports First Quarter 2026 Financial Results

Tue, 05 May 2026 16:05:00 -0400

Form 4 Adaptive Biotechnologies For: Apr 27 Filed by: RUBINSTEIN JULIE

Wed, 29 Apr 2026 19:09:00 -0400

si-local-file:///var/storage/secattach/20260429/26397675.html

Form 4 Adaptive Biotechnologies For: Apr 27 Filed by: RUBINSTEIN JULIE

Wed, 29 Apr 2026 19:09:00 -0400

si-local-file:///var/storage/secattach/20260429/26397675.html

Form 4 Adaptive Biotechnologies For: Apr 22 Filed by: RUBINSTEIN JULIE

Fri, 24 Apr 2026 18:30:00 -0400

si-local-file:///var/storage/secattach/20260424/26367701.html

Form 4 Adaptive Biotechnologies For: Apr 22 Filed by: RUBINSTEIN JULIE

Fri, 24 Apr 2026 18:30:00 -0400

si-local-file:///var/storage/secattach/20260424/26367701.html